Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 4 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 118Urinary Bladder Neoplasms 27Carcinoma, Renal Cell 25Kidney Neoplasms 19Neoplasms 14Neoplasm Metastasis 9Breast Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Prostatic Hyperplasia 5Pain 5Lung Neoplasms 5Liver Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Carcinoma, Hepatocellular 4Urologic Neoplasms 3Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Multiple Myeloma 3Kidney Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Uterine Cervical Neoplasms 2Tobacco Use Disorder 2Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Cancer Metastatic 2Pancreatic Neoplasms 2

Interventions

enzalutamide 1Prednisolone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Metastatic Castration-Resistant Prostate Cancer × Genitourinary × Clear all
NCT02405858 2025-02-03

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Janssen Pharmaceutical K.K.

Phase 4 Completed
51 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02116582 2024-12-06

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc

Phase 4 Completed
215 enrolled 11 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡